VettaFi's September rebalance cycle reshapes factor and thematic index ETFs

The mental model most people carry for an index ETF comes from the S&P 500: buy the benchmark, let the weights drift with price, and expect little to happen between reconstitutions. ETF Trends argued on Sept. 28 that the model fails for a large part of the index ETF market, where many funds run under strict rules-based methodologies that reconstitute and rebalance on a schedule, shifting constituent weights, capturing emerging trends and swapping in companies with improving fundamentals without a human manager's bias.

The occasion was the mid-September 2026 rebalancing cycle across benchmarks VettaFi manages, which the piece says reshaped factor and thematic portfolios. A disclosure at the foot of the article states that VettaFi is the index provider for OUSM, QGRO, THNR, UFO and VFLO and receives a licensing fee for each, and that none of those funds is issued, sponsored, endorsed or sold by VettaFi — the rulebook is written by one business, the funds that follow it are sold by others.

THNR's rebalance moved Gilead Sciences and Structure Therapeutics into a 20-stock index, a portfolio concentrated enough that its return still rides on Eli Lilly; the fund holds about $5.8 million. OUSM's quality screen produced 111 names in which the sector line binds harder than the single-name cap, so a fund labeled for quality keeps making its largest call by industry.

The label describes the selection rule, and a rulebook that reconstitutes on a schedule produces turnover a market-cap fund does not. The decisions are pre-committed rather than absent, and pre-commitment still means somebody chose the screen, the position cap and the industry line. The competitive ground has moved to mandate design, and a scheduled rebalance is mandate design in motion.

For advisors holding these funds, the calendar is the practical part: OUSM's screen resolves into a sector position, THNR's 20 names mean one holding can set the return, and both live in methodology documents that say what gets screened in and what gets dropped. The next reconstitution date is knowable before it happens — a different checklist than the one used for a market-cap fund, arriving on a date the provider publishes.